Alecensa (Alectinib HCl) Patent Expiration, LOE Window & CMS Spending
Alecensa (Alectinib HCl) by Roche / Genentech: FDA Orange Book core substance LOE 2031-05-29 (last listed 2035-04-24), 0 AB generics, $295.4M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Roche / Genentech |
| FDA Application & Pathway | N208434 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-05-29 |
| Last Listed Patent or Exclusivity Date | 2035-04-24 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $295.4M |
| 2024 Medicare Part D Spend | $246.7M |
| 2024 Medicaid Spend | $48.7M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 16.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.